Salvia Pratensis Exhibits in Vitro Anti-Cancer Effects in Triple-Negative Breast Cancer Through miR-34a-5p Signaling

Why It Matters

The study identifies a plant‑derived agent that selectively impairs aggressive TNBC cells, offering a potential new avenue for safer, targeted treatments in a cancer subtype with limited options.

Key Takeaways

• Salvia pratensis extract reduces TNBC cell viability 33%.
• Treatment increases mitochondrial ROS and induces G0/G1 arrest.
• miR‑34a‑5p expression rises fourfold, linking to apoptosis.
• Non‑tumorigenic MCF‑10A cells remain unaffected.
• Phytochemicals include rosmarinic acid and luteolin derivatives.

Pulse Analysis

Triple‑negative breast cancer remains a therapeutic blind spot, accounting for 15% of breast cancers yet lacking hormone‑driven targets. Conventional chemotherapy and immunotherapy deliver modest survival gains but are plagued by resistance and toxicity. Consequently, the oncology community has turned to nature’s chemical library, where roughly half of approved anticancer drugs originated, to uncover novel mechanisms that can outmaneuver TNBC’s aggressive biology.

In a recent Frontiers in Nutrition paper, scientists profiled methanolic leaf extracts from three native Italian species and pinpointed Salvia pratensis as uniquely potent against the MDA‑MB‑231 cell line. Rich in rosmarinic acid, salvianolic acids, and luteolin glycosides, the extract reduced metabolic activity, amplified mitochondrial superoxide production, and forced cells into G0/G1 arrest. Molecular profiling revealed down‑regulation of proliferation and stemness genes, a shift toward pro‑apoptotic BAX/BCL2 ratios, and, notably, a four‑fold up‑regulation of miR‑34a‑5p—a microRNA whose low expression predicts poorer TNBC outcomes. Mimicking miR‑34a‑5p alone reproduced much of the cytotoxic effect, underscoring its central role in the extract’s action.

The implications extend beyond academic curiosity. Salvia pratensis offers a blueprint for developing plant‑derived nutraceuticals or adjuvant therapies that could complement existing regimens, potentially lowering required chemotherapy doses and mitigating side effects. However, translating in‑vitro potency to clinical benefit demands rigorous pharmacokinetic studies, bioavailability assessments, and animal model validation. If these hurdles are cleared, the market for botanically sourced oncology agents—already valued in the billions—could expand to include a new class of miRNA‑modulating, ROS‑inducing compounds tailored for the most recalcitrant breast cancers.